<DOC>
	<DOCNO>NCT02613026</DOCNO>
	<brief_summary>The purpose study compare short-term long-term efficacy safety pirarubicin plus docetaxel ( AT group ) pirarubicin plus cyclophosphamide follow docetaxel ( AC-T group ) neoadjuvant chemotherapy breast cancer .</brief_summary>
	<brief_title>Comparative Analysis Efficacies Neoadjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>Based result NSABP ( National Surgical Adjuvant Breast Bowel Project ) B27 trial , anthracyclines ( A ) Taxanes ( T ) commonly recommend neoadjuvant chemotherapy breast cancer . Pirarubicin one anthracyclines embed DNA double strand , inhibits DNA replication RNA synthesis , thereby impede rapid growth cancer cell . Docetaxel one taxanes strengthen tubulin polymerization , inhibit microtubule depolymerization lead formation stable non functional microtubule bundle , destroy mitosis tumor cell .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<criteria>histopathologically diagnose stage IIII breast cancer ; clearly confirm ER , PR HER2 statuses ; state axillary lymph node determine relevant examination step ( puncture sentinel lymph node biopsy ) ; patient treat neoadjuvant therapy surgery . patient whose breast axillary lump receive excision biopsy ; patient severely abnormal organ function could tolerate chemotherapy , patient severe concomitant disease ; patient heart disease leave ventricular ejection fraction ( LVEF ) &lt; 50 % .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast tumor</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Pathological complete remission</keyword>
</DOC>